Oxford Covid-19 vaccine trial shows promise | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Sunday
October 01, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
SUNDAY, OCTOBER 01, 2023
Oxford Covid-19 vaccine trial shows promise

Coronavirus chronicle

TBS Report
20 July, 2020, 07:50 pm
Last modified: 21 July, 2020, 12:04 am

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca's Covid vaccine suffers a setback in nasal spray trial
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match

Oxford Covid-19 vaccine trial shows promise

AstraZeneca's is among the leading vaccine candidates against a pandemic that has claimed more than 600,000 lives, alongside others in mid and late-stage trial

TBS Report
20 July, 2020, 07:50 pm
Last modified: 21 July, 2020, 12:04 am
File Photo: Small bottles labelled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo
File Photo: Small bottles labelled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo

An experimental Covid-19 vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, a sign of progress in the high-stakes pursuit of a shot to defeat the pathogen.

The vaccine, called AZD1222 did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results published in The Lancet medical journal, reports Reuters.

Lead author  of the study, Oxford University's Andrew Pollard said: "We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period."

"However, we need more research before we can confirm the vaccine effectively protects against SARS-CoV-2 (Covid-19) infection, and for how long any protection lasts," he said.

AstraZeneca's is among the leading vaccine candidates against a pandemic that has claimed more than 600,000 lives, alongside others in mid and late-stage trials. These include shots being developed by China's Sinovac Biotech, another from state-owned Chinese firm Sinopharm, and one from the US biotech firm Moderna.

AstraZeneca Covid-19 vaccine likely to protect for a year - CEO

AstraZeneca has signed agreements with governments around the world to supply the vaccine should it prove effective and gain regulatory approval. The company has said it will not seek to profit from the vaccine during the pandemic.

CanSino coronavirus vaccine shows immune response in human trial

Researchers said the vaccine caused minor side effects more frequently than a control group, but some of these could be reduced by taking paracetamol, with no serious adverse events from the vaccine.

Key Step

Stimulating production of neutralizing antibodies is considered an important early step in testing. However, it doesn't prove a vaccine will be effective. Results from testing in animals had already shown the Oxford-AstraZeneca shot provoked an immune response.

The Phase 1 trial, which took place between April 23 and May 21, involved 1,077 healthy adults aged 18 to 55 with no history of Covid-19, reports Bloomberg.

A control group were given a meningitis vaccine as a placebo and 10 participants received two doses of the shot one month apart. The vaccine caused minor side effects, which could be reduced by taking paracetamol. There were no serious adverse events from the jab.

According to head of Oxford's Jenner Institute Adrian Hill, most of the participants in the study received a single dose of vaccine and Astra will prioritize a two-shot regimen in future testing.

"It gives higher titres of antibodies, which is important going forward," he said. Moderna will also test a two-dose regimen.

AstraZeneca said in a statement that a single dose of Oxford vaccine resulted in a four-fold increase in antibodies to the virus's spike protein in 95 percent of participants one month after injection .

SARS-CoV-2 uses the spike protein to enter cells. A T-cell response was induced in all participants who got the vaccine, peaking by day 14 after injection.

"It is good, not unexpected, but good to have it confirmed. The vaccine worked and developed the all-important neutralizing antibodies, in most cases after one shot and in all cases after 2 shots," said Ian Jones, professor of biomedical sciences at the University of Reading.

The Oxford shot is close to the front of the pack and has already begun final-stage tests among the other Covid-19 vaccine researches. AstraZeneca has said it may begin delivering doses to the UK as early as September.

"We want other companies to have vaccines that work as well because the world will get more vaccine sooner," Hill said.

"We just feel there is an advantage of having both arms of the immune system stimulated well."

AstraZeneca received a boost when the US pledged as much as $1.2 billion toward development. Under its agreement with the British drugmaker, the US could begin receiving supplies as early as October. The UK has also struck a supply agreement for the shot, but on Monday it secured access to other drugmakers' experimental vaccines to hedge its bets and garner enough doses to cover its population of 66 million. The UK government secured deals with Pfizer, BioNTech and Valneva SE.

Covid Fight

Companies and universities are relying on an array of approaches in the fight against Covid-19. The Oxford team has developed a technology that can speed up the process by using a harmless virus to carry some of the pathogen's genetic material into cells to generate an immune response. The proposed vaccine is made from a weakened version of a common cold virus that's genetically changed to make it unable to grow in humans.

Oxford has inserted genetic material from the surface spike protein of the SARS-CoV-2 virus as a way of tricking the immune system into fighting back. The platform stimulates both antibodies and high levels of killer T-cells, a type of white blood cell that helps the immune system destroy infection.

"We are very encouraged," Hill said.

While the test doesn't prove the vaccine will work, an optimistic Hill added: "I think we ae a bit more confident it should work this week than last week."

Top News

AstraZeneca / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Paperfly aborts flight
    Paperfly aborts flight
  • TBS sketch
    Visa curbs apply to those trying to gag media: Peter Haas
  • Obaidul Quader speaking at a peace and development rally arranged by the Dhaka District Awami League in Keraniganj this afternoon (26 September), protesting terrorism, militancy, anarchy, ill-politics and anti-state conspiracy of the BNP and Jamaat. Photo: Collected
    Why does BNP appeal for Khaleda's release to a govt they deem ‘illegal’: Quader

MOST VIEWED

  • BRACU, DU, JU, NSU lead Bangladeshi universities in World Rankings 2024
    BRACU, DU, JU, NSU lead Bangladeshi universities in World Rankings 2024
  • File photo of Rooppur Nuclear Power Plant/UNB
    First batch of uranium reaches Rooppur
  • Photo: BCB
    Shakib says he hasn't spoken with Litton since he broke his bat
  • Photo: Courtesy
    'No responsible captain could do that': Shakib directly blames Tamim for Afghanistan series loss
  • Khaleda Zia moved back to cabin from CCU
    Khaleda Zia moved back to cabin from CCU
  • BCL activist killed, 20 injured in AL-BNP clash in Chattogram
    BCL activist killed, 20 injured in AL-BNP clash in Chattogram

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca's Covid vaccine suffers a setback in nasal spray trial
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match

Features

Photo & Coffee Sketch: Touseful Isalm

A coffee conversation with Rumi

15h | Features
Photo: Collected

The top 3 smartwatches of 2023: A glimpse into the future

21h | Brands
In the Nannu Market area in Mirpur 11, there are 35 such shops that provide clothes-fitting services like shortening of pants, tightening of sleeves and shirts, and so on. Photo: Noor-A-Alam

How former RMG workers reinvent themselves as fitting tailors

18h | Panorama
Photo: Collected

Almost 30 years later, Friends merch is still ‘perfection’

20h | Brands

More Videos from TBS

Shakib-Tamim: From best friends to bitter enemies

Shakib-Tamim: From best friends to bitter enemies

10h | TBS SPORTS
Many urban workers are moving to villages

Many urban workers are moving to villages

11h | TBS Stories
How China is reaping the benefits of war without adding fuel to the fire?

How China is reaping the benefits of war without adding fuel to the fire?

12h | TBS World
90% of beggars arrested abroad are of Pakistani origin

90% of beggars arrested abroad are of Pakistani origin

14h | TBS World
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]